Key result
miRNA-targeted nanotherapies for hypertension remain preclinical, with zero candidates reaching clinical trials.
Why the study?
Hypertension management remains largely empirical, and circulating miRNAs are candidate noninvasive biomarkers and therapeutic targets for precision antihypertensive strategies, though discrepancies between cohorts exist and miRNA delivery platforms lack established clinical efficacy or safety.
Answers are grounded in this paper and cite their sources.
This review highlights that while circulating miRNAs and nanocarrier delivery systems show preclinical promise for precision hypertension management, clinical translation requires standardized assays, multi-cohort validation, and established clinical safety.
INTRODUCTION: Hypertension is a leading contributor to cardiovascular and renal morbidity worldwide, and its management remains largely empirical. MicroRNAs (miRNAs) regulate pathways central to blood-pressure homeostasis and are stable in the circulation, positioning them as candidate noninvasive biomarkers and therapeutic targets for precision antihypertensive strategies. AREAS COVERED: This review examines circulating miRNA signatures reported in hypertensive patients, including miR-21, miR-145, miR-122 and miR-155, and their association with target-organ damage. Discrepancies between cohorts are appraised in relation to sample matrix, comorbidities, detection platform and normalization, and the pre-analytical standardization required for reproducible measurement. Mechanistic roles in renin-angiotensin-aldosterone signaling, renal sodium handling, endothelial function and oxidative stress are discussed, with bioinformatics and machine-learning pipelines for biomarker discovery, their validation requirements, and preclinical nanocarrier platforms providing proof of concept for miRNA delivery without established clinical efficacy or safety. EXPERT OPINION: miRNA-guided diagnosis and therapy in hypertension remains preclinical; no miRNA nanomedicine has entered hypertension-focused clinical trials. Clinical translation will depend on harmonized sampling and normalization, externally validated multi-cohort machine-learning signatures, and nanocarriers with demonstrated cytosolic delivery and acceptable repeated-dose safety. Stepwise integration of these strands offers the most realistic route to translation.
No takes yet. Share an insight, caveat, or question.
Salah et al. (2026) conducted a review in Hypertension. miRNA bioinformatics and nanotechnology was evaluated. miRNA-guided diagnosis and nanocarrier therapy in hypertension remain preclinical, with 0 miRNA nanomedicines having entered hypertension-focused clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: